Dapagliflozin

Patients with albuminuric chronic kidney disease without diabetes can experience a significantly increased survival free of kidney failure if treated with the combination of angiotensin receptor blockers and SGLT2 inhibitors.

ORLANDO — In the 7 years since 2015, nephrologists have showed a 35-fold increased use of SGLT2 inhibitors, according to a presenter at ASN Kidney Week.

ORLANDO — In this video from ASN Kidney Week, Jula Inrig, MD, chief medical officer of Travere Therapeutics Inc., discusses the use of dapagliflozin with sparsentan as treatment for IgA nephropathy and focal segmental glomerulosclerosis.

In the United Kingdom, Germany and Spain, dapagliflozin with standard therapy is a cost-effective treatment for chronic kidney disease, according to data published in the Clinical Journal of the American Society of Nephrology.

The European Society of Cardiology Congress was held Aug. 26 to 29 in Barcelona, Spain, and online, having an in-person component for the first time since 2019.

NATIONAL HARBOR, Md. — In a DELIVER subgroup analysis, dapagliflozin conferred similar benefit in patients with HF with improved ejection fraction prior to trial enrollment compared with those with consistently high EF.

Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.

Dapagliflozin (Farxiga, AstraZeneca) vs. placebo in patients with HF and ejection fraction above 40%.

Among patients with chronic kidney disease and albuminuria treated with dapagliflozin, researchers did not identify a correlation between acute reduction in eGFR and higher rates of CKD progression.

In adults with HF with mildly reduced or preserved ejection fraction, dapagliflozin significantly reduced risk for CV death and worsening HF compared with placebo, with no attenuation of treatment benefit for patients with the highest EF.